<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRAVASTATIN SODIUM- pravastatin sodiumÂ tabletÂ </strong><br>International Labs, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to useÂ pravastatin sodium tablets USPÂ safely and effectively. See full prescribing information for pravastatin sodium tablets USP.</span><br><br><span class="Bold">PRAVASTATIN SODIUM tablets USP forÂ oral use.</span><br><span class="Bold">Initial U.S. Approval: 1991</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Pravastatin Sodium Tablets USP are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to:  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">â€¢ Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. (1.1)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">â€¢ Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. (1.2)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">â€¢ Reduce elevated serum TG levels in patients with <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>. (1.2)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">â€¢ Treat patients with primary dysbetalipoproteinemia who are not responding to diet. (1.2)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">â€¢ Treat children and adolescent patients ages 8 years and older with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> after failing an adequate trial of diet therapy. (1.2)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">Limitations of use:  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">â€¢ Pravastatin Sodium Tablets USP have not been studied inÂ <span class="Italics">Fredrickson</span>Â Types I and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>. (1.3)  (<a href="#section-1">1</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">â€¢ Adults: the recommended starting dose is 40 mg once daily. Use 80 mg dose only for patients not reaching LDL-C goal with 40 mg. (2.2)  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">â€¢ Significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: the recommended starting dose is 10 mg once daily. (2.2)  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">â€¢ Children (ages 8 to 13 years, inclusive): the recommended starting dose is 20 mg once daily. (2.3)  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">â€¢ Adolescents (ages 14 to 18 years): the recommended starting dose is 40 mg once daily. (2.3)  (<a href="#section-2">2</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 20 mg and 40 mg. (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">â€¢ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication. (4.1, 6.2, 11)  (<a href="#section-4">4</a>)</p>
<p class="Highlighta">â€¢ Active liver disease or unexplained, persistent elevations of serum transaminases. (4.2, 5.2)  (<a href="#section-4">4</a>)</p>
<p class="Highlighta">â€¢ Women who are pregnant or may become pregnant. (4.3, 8.1)  (<a href="#section-4">4</a>)</p>
<p class="Highlighta">â€¢ Nursing mothers. (4.4, 8.3)  (<a href="#section-4">4</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">â€¢ Skeletal muscle effects (e.g., <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>): predisposing factors include advanced age (â‰¥ 65), uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients should be advised to promptly report to their physician any unexplained and/or persistent <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Pravastatin therapy should be discontinued if <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. (5.1, 8.5)  (<a href="#section-5">5</a>)</p>
<p class="Highlighta">â€¢ Liver enzyme abnormalities: persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter. (5.2)  (<a href="#section-5">5</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In short-term clinical trials, the most commonly reported adverse reactions (â‰¥ 2% and &gt; placebo) regardless of causality were: <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (6.1)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537 orÂ <br>drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">â€¢ Concomitant lipid-lowering therapies: use with fibrates or lipid-modifying doses (â‰¥ 1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with pravastatin sodium. (7)  (<a href="#section-7">7</a>)</p>
<p class="Highlighta">â€¢ Cyclosporine: combination increases exposure. Limit pravastatin to 20 mg once daily. (2.5, 7.1)  (<a href="#section-7">7</a>)</p>
<p class="Highlighta">â€¢ Clarithromycin: combination increases exposure. Limit pravastatin to 40 mg once daily. (2.6, 7.2)  (<a href="#section-7">7</a>)</p>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_5b872bf7-ac38-4edd-87c0-578e543e964b"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and other nonpharmacologic measures alone has been inadequate.</p>
<p><span class="Bold">1.1 Prevention of Cardiovascular Disease</span></p>
<p>In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), Pravastatin Sodium Tablets USP are indicated to:</p>
<p>â€¢ reduce the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI).</p>
<p>â€¢ reduce the risk of undergoing myocardial revascularization procedures.</p>
<p>â€¢ reduce the risk of cardiovascular mortality with no increase in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from non-cardiovascular causes.</p>
<p><span class="Bold">1.2 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span></span></p>
<p>Pravastatin Sodium Tablets USP are indicated:</p>
<p>â€¢ as an adjunct to diet to reduce elevated total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (Total-C), low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) in patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> (<span class="Italics">Fredrickson</span>Â Types IIa and IIb).<span class="Sup">1</span></p>
<p>â€¢ as an adjunct to diet for the treatment of patients with elevated serum TG levels (<span class="Italics">Fredrickson</span>Â Type IV).</p>
<p>â€¢ for the treatment of patients with primary dysbetalipoproteinemia (<span class="Italics">Fredrickson</span>Â Type III) who do not respond adequately to diet.</p>
<p>â€¢ as an adjunct to diet and lifestyle modification for treatment of <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present:</p>
<p>a. LDL-C remains â‰¥ 190 mg/dL or</p>
<p>b. LDL-C remains â‰¥ 160 mg/dL and:</p>
<p>â€¢ there is a positive family history of premature cardiovascular disease (CVD) or</p>
<p>â€¢ two or more other CVD risk factors are present in the patient.</p>
<p><span class="Bold">1.3 Limitations of Use</span></p>
<p>Pravastatin Sodium Tablets USP have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (<span class="Italics">Fredrickson</span>Â Types I and V).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_a7d94d49-ec85-4a1e-ab80-baefa662e12d"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">2.1 General Dosing Information</span></p>
<p>The patient should be placed on a standard <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering diet before receiving pravastatin sodium tablets and should continue on this diet during treatment with pravastatin sodium tablets [see NCEP Treatment Guidelines for details on dietary therapy].</p>
<p><span class="Bold">2.2 Adult Patients</span></p>
<p>The recommended starting dose is 40 mg once daily. If a daily dose of 40 mg does not achieve desired <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels, 80 mg once daily is recommended. In patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, a starting dose of 10 mg daily is recommended. Pravastatin sodium tablets can be administered orally as a single dose at any time of the day, with or without food. Since the maximal effect of a given dose is seen within 4 weeks, periodic lipid determinations should be performed at this time and dosage adjusted according to the patientâ€™s response to therapy and established treatment guidelines.</p>
<p><span class="Bold">2.3 Pediatric Patients</span></p>
<p><span class="Bold">Children (Ages 8 to 13 Years, Inclusive)</span></p>
<p>The recommended dose is 20 mg once daily in children 8 to 13 years of age. Doses greater than 20 mg have not been studied in this patient population.</p>
<p><span class="Bold">Adolescents (Ages 14 to 18 Years)</span></p>
<p>The recommended starting dose is 40 mg once daily in adolescents 14 to 18 years of age. Doses greater than 40 mg have not been studied in this patient population.</p>
<p>Children and adolescents treated with pravastatin should be reevaluated in adulthood and appropriate changes made to their <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering regimen to achieve adult goals for LDL-C [<span class="Italics">see Indications and Usage (1.2)</span>].</p>
<p><span class="Bold">2.4 Concomitant Lipid-Altering Therapy</span></p>
<p>Pravastatin sodium tablets may be used with bile acid resins. When administering a bile-acid-binding resin (e.g., cholestyramine, colestipol) and pravastatin, pravastatin sodium tablets should be given either 1 hour or more before or at least 4 hours following the resin [<span class="Italics">see Clinical Pharmacology (12.3)</span>].</p>
<p><span class="Bold">2.5 Dosage in Patients Taking Cyclosporine</span></p>
<p>In patients taking immunosuppressive drugs such as cyclosporine concomitantly with pravastatin, therapy should begin with 10 mg of pravastatin sodium once-a-day at bedtime and titration to higher doses should be done with caution. Most patients treated with this combination received a maximum pravastatin sodium dose of 20 mg/day. In patients taking cyclosporine, therapy should be limited to 20 mg of pravastatin sodium once daily [<span class="Italics">see Warnings and Precautions (5.1) and Drug Interactions (7.1)</span>].</p>
<p><span class="Bold">2.6 Dosage in Patients Taking Clarithromycin</span></p>
<p>In patients taking clarithromycin, therapy should be limited to 40 mg of pravastatin sodium once daily [<span class="Italics">see Drug Interactions (7.2)</span>].</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_a39679e1-0972-49d3-aced-f592e22991ff"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="Bold">Pravastatin sodium tablets USP</span>Â are supplied as:</p>
<p><span class="Bold">20 mg tablets:</span>Â Light-yellow, unscored, round tablet, debossed â€œTEVAâ€? on one side and â€œ7201â€? on the other side.</p>
<p><span class="Bold">40 mg tablets:</span>Â Light-green, unscored, round tablet, debossed â€œTEVAâ€? on one side and â€œ7202â€? on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_f6c51c58-c587-4b9b-9f9b-c529f1ac0ac9"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication.</p>
<p><span class="Bold">4.2 Liver</span></p>
<p>Active liver disease or unexplained, persistent elevations of serum transaminases [<span class="Italics">see Warnings and Precautions (5.2)</span>].</p>
<p><span class="Bold">4.3 Pregnancy</span></p>
<p><span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and other products of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since statins decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, they are contraindicated during pregnancy and in nursing mothers. PRAVASTATIN SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this class of drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus [<span class="Italics">see Use in Specific Populations (8.1)</span>].</p>
<p><span class="Bold">4.4 Nursing Mothers</span></p>
<p>A small amount of pravastatin is excreted in human breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require pravastatin sodium tablet treatment should not breastfeed their infants [<span class="Italics">see Use in Specific Populations (8.3)</span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_23938068-8901-4eaa-aa81-781f91dc199d"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"><span class="Bold">5.1 Skeletal Muscle</span></p>
<p><span class="Bold">Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> have been reported with pravastatin and other drugs in this class.</span>Â A history of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> may be a risk factor for the development of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Such patients merit closer monitoring for skeletal muscle effects.</p>
<p>Uncomplicated <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> has also been reported in pravastatin-treated patients [<span class="Italics">see Adverse Reactions (6)</span>]. <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>, defined as muscle aching or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in conjunction with increases in creatine phosphokinase (CPK) values to greater than 10 times the upper limit of normal (ULN), was rare (&lt; 0.1%) in pravastatin clinical trials. <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> should be considered in any patient with diffuse <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, muscle <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and/or marked elevation of CPK. Predisposing factors include advanced age (â‰¥ 65), uncontrolled <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (IMNM), an autoimmune <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, associated with statin use. IMNM is characterized by: proximal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and elevated serum CPK, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> without significant <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and improvement with immunosuppressive agents.</p>
<p>All patients should be advised to promptly report to their physician unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if muscle signs and symptoms persist after discontinuing pravastatin sodium.</p>
<p><span class="Bold">Pravastatin therapy should be discontinued if markedly elevated CPK levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. Pravastatin therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, e.g., <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; major surgery; <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>.</span></p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with statins is increased with concurrent therapy with either erythromycin, cyclosporine, niacin, or fibrates. However, neither <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> nor significant increases in CPK levels have been observed in 3 reports involving a total of 100 post-transplant patients (24 renal and 76 cardiac) treated for up to 2 years concurrently with pravastatin 10 to 40 mg and cyclosporine. Some of these patients also received other concomitant immunosuppressive therapies. Further, in clinical trials involving small numbers of patients who were treated concurrently with pravastatin and niacin, there were no reports of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. Also, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> was not reported in a trial of combination pravastatin (40 mg/day) and gemfibrozil (1200 mg/day), although 4 of 75 patients on the combination showed marked CPK elevations versus 1 of 73 patients receiving placebo. There was a trend toward more frequent CPK elevations and patient withdrawals due to musculoskeletal symptoms in the group receiving combined treatment as compared with the groups receiving placebo, gemfibrozil, or pravastatin monotherapy.Â <span class="Bold">The use of fibrates alone may occasionally be associated with <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. The benefit of further alterations in lipid levels by the combined use of pravastatin sodium with fibrates should be carefully weighed against the potential risks of this combination.</span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with pravastatin coadministered with colchicine, and caution should be exercised when prescribing pravastatin with colchicine [<span class="Italics">see Drug Interactions (7.3)</span>].</p>
<p><span class="Bold">5.2 Liver</span></p>
<p>Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. In 3 long-term (4.8 to 5.9 years), placebo-controlled clinical trials, 19,592 subjects (19,768 randomized) were exposed to pravastatin or placebo [<span class="Italics">see Clinical Studies (14)</span>]. In an analysis of serum transaminase values (ALT, AST), incidences of marked abnormalities were compared between the pravastatin and placebo treatment groups; a marked abnormality was defined as a post-treatment test value greater than 3 times the upper limit of normal for subjects with pretreatment values less than or equal to the upper limit of normal, or 4 times the pretreatment value for subjects with pretreatment values greater than the upper limit of normal but less than 1.5 times the upper limit of normal. Marked abnormalities of ALT or AST occurred with similar low frequency (â‰¤ 1.2%) in both treatment groups. Overall, clinical trial experience showed that liver function test abnormalities observed during pravastatin therapy were usually asymptomatic, not associated with <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, and did not appear to be related to treatment duration. In a 320 patient placebo-controlled clinical trial, subjects with chronic (&gt; 6 months) stable liver disease, due primarily to <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C or non-<span class="product-label-link" type="condition" conceptid="193256" conceptname="Alcoholic fatty liver">alcoholic fatty liver</span> disease, were treated with 80 mg pravastatin or placebo for up to 9 months. The primary safety endpoint was the proportion of subjects with at least one ALT â‰¥ 2 times the upper limit of normal for those with normal ALT (â‰¤ the upper limit of normal) at baseline or a doubling of the baseline ALT for those with elevated ALT (&gt; the upper limit of normal) at baseline. By Week 36, 12 out of 160 (7.5%) subjects treated with pravastatin met the prespecified safety ALT endpoint compared to 20 out of 160 (12.5%) subjects receiving placebo. Conclusions regarding liver safety are limited since the study was not large enough to establish similarity between groups (with 95% confidence) in the rates of ALT elevation.</p>
<p><span class="Bold">It is recommended that liver function tests be performed prior to the initiation of therapy and when clinically indicated.</span></p>
<p>Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of pravastatin [<span class="Italics">see Contraindications (4.2)</span>]. Caution should be exercised when pravastatin is administered to patients who have a recent (&lt; 6 months) history of liver disease, have signs that may suggest liver disease (e.g., unexplained aminotransferase elevations, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>), or are heavy users of alcohol.</p>
<p>There have been rare postmarketing reports of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking statins, including pravastatin. If serious <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with clinical symptoms and/or <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs during treatment with pravastatin sodium, promptly interrupt therapy. If an alternate etiology is not found do not restart pravastatin sodium.</p>
<p><span class="Bold">5.3 Endocrine Function</span></p>
<p>Statins interfere with <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and lower circulating <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels and, as such, might theoretically blunt adrenal or gonadal steroid hormone production. Results of clinical trials with pravastatin in males and post-menopausal females were inconsistent with regard to possible effects of the drug on basal steroid hormone levels. In a study of 21 males, the mean testosterone response to human chorionic gonadotropin was significantly reduced (p &lt; 0.004) after 16 weeks of treatment with 40 mg of pravastatin. However, the percentage of patients showing a â‰¥ 50% rise in plasma testosterone after human chorionic gonadotropin stimulation did not change significantly after therapy in these patients. The effects of statins on spermatogenesis and fertility have not been studied in adequate numbers of patients. The effects, if any, of pravastatin on the pituitary-gonadal axis in pre-menopausal females are unknown. Patients treated with pravastatin who display clinical evidence of endocrine dysfunction should be evaluated appropriately. Caution should also be exercised if a statin or other agent used to lower <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels is administered to patients also receiving other drugs (e.g., ketoconazole, spironolactone, cimetidine) that may diminish the levels or activity of steroid hormones.</p>
<p>In a placebo-controlled study of 214 pediatric patients with HeFH, of which 106 were treated with pravastatin (20 mg in the children aged 8 to 13 years and 40 mg in the adolescents aged 14 to 18 years) for 2 years, there were no detectable differences seen in any of the endocrine parameters (ACTH, cortisol, DHEAS, FSH, LH, TSH, estradiol [girls] or testosterone [boys]) relative to placebo. There were no detectable differences seen in height and weight changes, testicular volume changes, or Tanner score relative to placebo.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_467a679a-54b6-4690-b40c-e381c5ae33b0"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Pravastatin is generally well tolerated; adverse reactions have usually been mild and transient. In 4 month-long placebo-controlled trials, 1.7% of pravastatin-treated patients and 1.2% of placebo-treated patients were discontinued from treatment because of adverse experiences attributed to study drug therapy; this difference was not statistically significant.</p>
<p><span class="Bold">6.1 Adverse Clinical Events</span></p>
<p><span class="Bold">Short-Term Controlled Trials</span></p>
<p>In the pravastatin sodium placebo-controlled clinical trials database of 1313 patients (age range 20 to 76 years, 32.4% women, 93.5% Caucasians, 5% Blacks, 0.9% Hispanics, 0.4% Asians, 0.2% Others) with a median treatment duration of 14 weeks, 3.3% of patients on pravastatin sodium and 1.2% patients on placebo discontinued due to adverse events regardless of causality. The most common adverse reactions that led to treatment discontinuation and occurred at an incidence greater than placebo were: liver function test increased, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>/<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>All adverse clinical events (regardless of causality) reported in â‰¥ 2% of pravastatin-treated patients in placebo-controlled trials of up to 8 months duration are identified inÂ <span class="Bold">Table 1</span>:</p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="7"><p class="First"><span class="Bold">Table 1: Adverse Events in â‰¥ 2% of Patients Treated With Pravastatin 5 to 40 mg and at an Incidence Greater Than Placebo in Short-Term Placebo-Controlled Trials (% of Patients)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Body System/Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">5 mg</span></p>
<p><span class="Bold">N = 100</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">10 mg</span></p>
<p><span class="Bold">N = 153</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">20 mg</span></p>
<p><span class="Bold">N = 478</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">40 mg</span></p>
<p><span class="Bold">N = 171</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Any Dose</span></p>
<p><span class="Bold">N = 902</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">N = 411</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Cardiovascular</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Dermatologic</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Gastrointestinal</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>/<br><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Abdominal<br>Distension</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">General</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Musculoskeletal</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Musculoskeletal<br><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Nervous System</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Respiratory</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Upper Respiratory</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Investigation</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">ALT Increased</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">g-GT Increased</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.2</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">CPK Increased</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.6</p></td>
</tr>
</tbody>
</table>
<p>The safety and tolerability of pravastatin sodium at a dose of 80 mg in 2 controlled trials with a mean exposure of 8.6 months was similar to that of pravastatin sodium at lower doses except that 4 out of 464 patients taking 80 mg of pravastatin had a single elevation of CK &gt; 10 times ULN compared to 0 out of 115 patients taking 40 mg of pravastatin.</p>
<p><span class="Bold">Long-Term Controlled Morbidity and Mortality Trials</span></p>
<p>In the pravastatin sodium placebo-controlled clinical trials database of 21,483 patients (age range 24 to 75 years, 10.3% women, 52.3% Caucasians, 0.8% Blacks, 0.5% Hispanics, 0.1% Asians, 0.1% Others, 46.1% Not Recorded) with a median treatment duration of 261 weeks, 8.1% of patients on pravastatin sodium and 9.3% patients on placebo discontinued due to adverse events regardless of causality.</p>
<p>Adverse event data were pooled from several double-blind, placebo-controlled trials (e.g., West of Scotland Coronary Prevention Study [WOS]; Pravastatin Limitation of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> in the Coronary Arteries study [PLAC I]; Pravastatin, Lipids and <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> in the Carotids study [PLAC II]; Regression Growth Evaluation Statin Study [REGRESS]; and Kuopio <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> Prevention Study [KAPS]) involving a total of 10,764 patients treated with pravastatin 40 mg and 10,719 patients treated with placebo. The safety and tolerability profile in the pravastatin group was comparable to that of the placebo group. Patients were exposed to pravastatin for a mean of 4 to 5.1 years in, among other trials, WOS and 1.9 to 2.9 years in PLAC I, PLAC II, KAPS, and REGRESS. In these long-term trials, the most common reasons for discontinuation were mild, non-specific gastrointestinal complaints. Collectively, these trials represent 47,613 patient-years of exposure to pravastatin. All clinical adverse events (regardless of causality) occurring in â‰¥ 2% of patients treated with pravastatin in these studies are identified inÂ <span class="Bold">Table 2</span>.</p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First"><span class="Bold">Table 2: Adverse Events in â‰¥ 2% of Patients Treated With Pravastatin 40 mg and at an Incidence Greater Than Placebo in Long-Term Placebo-Controlled Trials</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Body System/Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Pravastatin</span></p>
<p><span class="Bold">(N = 10,764)</span></p>
<p><span class="Bold">% of patients</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(N = 10,719)</span></p>
<p><span class="Bold">% of patients</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Dermatologic</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (including <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">General</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Musculoskeletal</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">24.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">24.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Cramp</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Musculoskeletal Traumatism</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Nervous System</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep Disturbance</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>/<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Renal/Genitourinary</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Respiratory</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">21.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Sinus Abnormality</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4028970" conceptname="Tracheobronchitis">Tracheobronchitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Special Senses</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Vision Disturbance (includes <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>,</p>
<p><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2.9</p></td>
</tr>
</tbody>
</table>
<p>In addition to the events listed above in the long-term trials table, events of probable, possible, or uncertain relationship to study drug that occurred in &lt; 2% of pravastatin-treated patients in the long-term trials included the following:</p>
<p><span class="Italics">Dermatologic:</span>Â scalp hair abnormality (including <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics">Endocrine/Metabolic:</span>Â <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, libido change.</p>
<p><span class="Italics">General:</span>Â <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>.</p>
<p><span class="Italics">Immunologic:</span>Â <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> head/neck.</p>
<p><span class="Italics">Musculoskeletal:</span>Â <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</p>
<p><span class="Italics">Nervous System:</span>Â <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> (including <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>).</p>
<p><span class="Italics">Special Senses:</span>Â <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>.</p>
<p><span class="Bold">6.2 Postmarketing Experience</span></p>
<p>In addition to the events reported above, as with other drugs in this class, the following events have been reported rarely during postmarketing experience with pravastatin sodium, regardless of causality assessment:</p>
<p><span class="Italics">Musculoskeletal:</span>Â <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with statin use [<span class="Italics">see Warnings and Precautions (5.1)</span>].</p>
<p><span class="Italics">Nervous System:</span>Â dysfunction of certain cranial nerves (including alteration of taste, impairment of extraocular movement, <span class="product-label-link" type="condition" conceptid="434657" conceptname="Weakness of face muscles">facial paresis</span>), peripheral nerve <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">palsy</span>.</p>
<p>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (e.g., <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span>Â <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>-like syndrome, <span class="product-label-link" type="condition" conceptid="255348" conceptname="Polymyalgia rheumatica">polymyalgia rheumatica</span>, <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, positive ANA, ESR increase, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>).</p>
<p><span class="Italics">Gastrointestinal:</span>Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (including <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>), <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, fatty change in liver, cirrhosis, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span>, fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>.</p>
<p><span class="Italics">Dermatologic:</span>Â a variety of skin changes (e.g., <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, discoloration, dryness of mucous membranes, changes to hair/nails).</p>
<p><span class="Italics">Renal:</span>Â urinary abnormality (including <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, frequency, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>).</p>
<p><span class="Italics">Respiratory:</span>Â <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p><span class="Italics">Reproductive:</span>Â <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.</p>
<p><span class="Italics">Laboratory Abnormalities:</span>Â liver function test abnormalities, thyroid function abnormalities.</p>
<p><span class="Bold">6.3 Laboratory Test Abnormalities</span></p>
<p>Increases in ALT, AST values and CPK have been observed [<span class="Italics">see Warnings and Precautions (5.1, 5.2)</span>].</p>
<p>Transient, asymptomatic <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> has been reported. Eosinophil counts usually returned to normal despite continued therapy. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> have been reported with statins.</p>
<p><span class="Bold">6.4 Pediatric Patients</span></p>
<p>In a 2 year, double-blind, placebo-controlled study involving 100 boys and 114 girls with HeFH (n = 214; age range 8 to 18.5 years, 53% female, 95% Caucasians, &lt; 1% Blacks, 3% Asians, 1% Other), the safety and tolerability profile of pravastatin was generally similar to that of placebo [<span class="Italics">see Warnings and Precautions (5.3), Use in Specific Populations (8.4), and Clinical Pharmacology (12.3)</span>].</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_eb7cd3c5-4460-4619-b099-0bf10f473e3f"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Bold">For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> increases [<span class="Italics">see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)</span>].</span></p>
<p><span class="Bold">7.1 Cyclosporine</span></p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased with concomitant administration of cyclosporine. Limit pravastatin to 20 mg once daily for concomitant use with cyclosporine [<span class="Italics">see Dosage and Administration (2.5), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)</span>].</p>
<p><span class="Bold">7.2 Clarithromycin</span></p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased with concomitant administration of clarithromycin. Limit pravastatin to 40 mg once daily for concomitant use with clarithromycin [<span class="Italics">see Dosage and Administration (2.6), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)</span>].</p>
<p><span class="Bold">7.3 Colchicine</span></p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> is increased with concomitant administration of colchicine [<span class="Italics">see Warnings and Precautions (5.1)</span>].</p>
<p><span class="Bold">7.4 Gemfibrozil</span></p>
<p>Due to an increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of pravastatin sodium with gemfibrozil should be avoided [<span class="Italics">see Warnings and Precautions (5.1)</span>].</p>
<p><span class="Bold">7.5 Other Fibrates</span></p>
<p>Because it is known that the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, pravastatin sodium should be administered with caution when used concomitantly with other fibrates [<span class="Italics">see Warnings and Precautions (5.1)</span>].</p>
<p><span class="Bold">7.6 Niacin</span></p>
<p>The risk of skeletal muscle effects may be enhanced when pravastatin is used in combination with niacin; a reduction in pravastatin sodium dosage should be considered in this setting [<span class="Italics">see Warnings and Precautions (5.1)</span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_8690b95c-ba2e-4260-9509-20f9fe9701d5"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_674844e0-11bb-4728-b9c7-a1b4ed09a561"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects</span></p>
<p><span class="Underline">Pregnancy Category X</span></p>
<p>[<span class="Italics">See Contraindications (4.3).</span>]</p>
<p>Safety in pregnant women has not been established. Available data in women inadvertently taking pravastatin while pregnant do not suggest any adverse clinical events. However, there are no adequate and well-controlled studies in pregnant women. Therefore, it is not known whether pravastatin can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Pravastatin should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus and patients have been informed of the potential hazards.</p>
<p>Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In a review<span class="Sup">2</span>Â of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed what would be expected in the general population. The number of cases is adequate to exclude a â‰¥ 3 to 4 fold increase in congenital anomalies over the background incidence. In 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. As safety in pregnant women has not been established and there is no apparent benefit to therapy with pravastatin sodium during pregnancy [<span class="Italics">see Contraindications (4.3)</span>], treatment should be immediately discontinued as soon as pregnancy is recognized. Pravastatin sodium should be administered to women of childbearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards.</p>
<p>Pravastatin was neither embryolethal nor teratogenic in rats at doses up to 1000 mg/kg daily or in rabbits at doses of up to 50 mg/kg daily. These doses resulted in 10 times (rabbit) or 120 times (rat) the human exposure at 80 mg/day maximum recommended human dose (MRHD) based on surface area (mg/m<span class="Sup">2</span>).</p>
<p>In pregnant rats given oral gavage doses of 4, 20, 100, 500, and 1000 mg/kg/day from gestation days 7 through 17 (organogenesis) increased mortality of offspring and skeletal anomalies were observed at 100 mg/kg/day systemic exposure, 10 times the human exposure at 80 mg/day MRHD based on body surface area (mg/m<span class="Sup">2</span>).</p>
<p>In pregnant rats given oral gavage doses of 10, 100, and 1000 mg/kg/day from gestation day 17 through lactation day 21 (weaning) increased mortality of offspring and <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> were observed at 100 mg/kg/day systemic exposure, 12 times the human exposure at 80 mg/day MRHD based on body surface area (mg/m<span class="Sup">2</span>).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_d638291f-3381-4711-8f05-d55566258be5"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">A small amount of pravastatin is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants, women taking pravastatin sodium should not nurse [<span class="Italics">see Contraindications (4.4)</span>].</p>
<p>Pravastatin crosses the placenta and is found in fetal tissue at 30% maternal plasma levels following a single 20 mg/kg dose given to pregnant rats on gestation day 18. Similar studies in lactating rats indicate secretion of pravastatin into breast milk at 0.2 to 6.5 times higher levels than maternal plasma at exposures equivalent to 2 times human exposure at the MRHD.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_a988d76a-763d-401e-aced-0c844d257044"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of pravastatin sodium in children and adolescents from 8 to 18 years of age have been evaluated in a placebo-controlled study of 2 years duration. Patients treated with pravastatin had an adverse experience profile generally similar to that of patients treated with placebo with <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> commonly reported in both treatment groups [<span class="Italics">see Adverse Reactions (6.4)</span>].Â <span class="Bold">Doses greater than 40 mg have not been studied in this population.</span>Â Children and adolescent females of childbearing potential should be counseled on appropriate contraceptive methods while on pravastatin therapy [<span class="Italics">see Contraindications (4.3) and Use in Specific Populations (8.1)</span>]. For dosing information [<span class="Italics">see Dosage and Administration (2.3)</span>].</p>
<p>Double-blind, placebo-controlled pravastatin studies in children less than 8 years of age have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_898e179c-6bd4-45f2-a93f-95dc28cb87c1"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The beneficial effect of pravastatin in elderly subjects in reducing cardiovascular events and in modifying lipid profiles was similar to that seen in younger subjects. The adverse event profile in the elderly was similar to that in the overall population. Other reported clinical experience has not identified differences in responses to pravastatin between elderly and younger patients.</p>
<p>Mean pravastatin AUCs are slightly (25% to 50%) higher in elderly subjects than in healthy young subjects, but mean maximum plasma concentration (C<span class="Sub">max</span>), time to maximum plasma concentration (T<span class="Sub">max</span>), and half-life (tÂ½) values are similar in both age groups and substantial accumulation of pravastatin would not be expected in the elderly [<span class="Italics">see Clinical Pharmacology (12.3)</span>].</p>
<p>Since advanced age (â‰¥ 65 years) is a predisposing factor for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, pravastatin sodium should be prescribed with caution in the elderly [<span class="Italics">see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c7efe10e-f36d-4023-9844-3820010c9761"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Homozygous Familial Hypercholesterolemia</span></h2>
<p class="First">Pravastatin has not been evaluated in patients with rare <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">homozygous familial hypercholesterolemia</span>. In this group of patients, it has been reported that statins are less effective because the patients lack functional LDL receptors.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_f3748f89-fd95-4ed7-bbb9-e3161d84d122"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">To date, there has been limited experience with overdosage of pravastatin. If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, it should be treated symptomatically with laboratory monitoring and supportive measures should be instituted as required.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_18121a0f-0e8a-4c28-89d9-a28f75d7facc"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Pravastatin sodium, USP is one of a class of lipid-lowering compounds, the statins, which reduce <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> biosynthesis. These agents are competitive inhibitors of HMG-CoA reductase, the enzyme catalyzing the early rate-limiting step in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> biosynthesis, conversion of HMG-CoA to mevalonate.</p>
<p>Pravastatin sodium, USP is designated chemically as 1-naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-Î²,Î´,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1<span class="Italics">S</span>-[1Î±Â (Î²<span class="Italics">S</span>*,Î´<span class="Italics">S</span>*),2Î±,6Î±,8Î²(<span class="Italics">R</span>*),8aÎ±]]-. It has the following structural formula:</p>
<div class="Figure">
<img alt="Pravastatin Sodium Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88295e57-9167-48a0-b52f-6ec9cef61109&amp;name=pravastatin-1.jpg"><p class="MultiMediaCaption">Pravastatin Sodium Structural Formula</p>
</div>
<p>Pravastatin sodium, USP is an odorless, white to off-white, fine or crystalline powder. It is a relatively polar hydrophilic compound with a partition coefficient (octanol/water) of 0.59 at a pH of 7. It is soluble in methanol and water (&gt; 300 mg/mL), slightly soluble in isopropanol, and practically insoluble in acetone, acetonitrile, chloroform, and ether.</p>
<p>Pravastatin Sodium Tablets USP are available for oral administration as 20 mg and 40 mg tablets. Inactive ingredients include: calcium phosphate dibasic anhydrous, croscarmellose sodium, crospovidone, lactose anhydrous, microcrystalline cellulose, povidone and sodium stearyl fumarate. Additionally, the 20 mg tablet contains ferric oxide yellow; the 40 mg tablet contains FD&amp;C Blue No. 1 Aluminum Lake and Yellow D&amp;C No. 10.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_dd3c72ce-c8a2-4766-96dc-733e9020aa79"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_95fc8bca-5181-413d-bc91-378b1f98ca8c"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. In addition, pravastatin reduces VLDL and TG and increases HDL-C.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_3c8480d6-fe47-4eae-9d52-6866437e725c"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold">General</span></p>
<p><span class="Bold">Absorption:</span>Â Pravastatin sodium is administered orally in the active form. In studies in man, peak plasma pravastatin concentrations occurred 1 to 1.5 hours upon oral administration. Based on urinary recovery of total radiolabeled drug, the average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. While the presence of food in the gastrointestinal tract reduces systemic bioavailability, the lipid-lowering effects of the drug are similar whether taken with or 1 hour prior to meals.</p>
<p>Pravastatin plasma concentrations, including area under the concentration-time curve (AUC), C<span class="Sub">max</span>, and steady-state minimum (C<span class="Sub">min</span>), are directly proportional to administered dose. Systemic bioavailability of pravastatin administered following a bedtime dose was decreased 60% compared to that following an AM dose. Despite this decrease in systemic bioavailability, the efficacy of pravastatin administered once daily in the evening, although not statistically significant, was marginally more effective than that after a morning dose.</p>
<p>The coefficient of variation (CV), based on between-subject variability, was 50% to 60% for AUC. The geometric means of pravastatin C<span class="Sub">max</span>Â and AUC following a 20 mg dose in the fasted state were 26.5 ng/mL and 59.8 ng*hr/mL, respectively.</p>
<p>Steady-state AUCs, C<span class="Sub">max</span>, and C<span class="Sub">min</span>Â plasma concentrations showed no evidence of pravastatin accumulation following once or twice daily administration of pravastatin sodium tablets.</p>
<p><span class="Bold">Distribution:</span>Â Approximately 50% of the circulating drug is bound to plasma proteins.</p>
<p><span class="Bold">Metabolism:</span>Â The major biotransformation pathways for pravastatin are: (a) isomerization to 6-epi pravastatin and the 3Î±-hydroxyisomer of pravastatin (SQ 31,906) and (b) enzymatic ring hydroxylation to SQ 31,945. The 3Î±-hydroxyisomeric metabolite (SQ 31,906) has 1/10 to 1/40 the HMG-CoA reductase inhibitory activity of the parent compound. Pravastatin undergoes extensive first-pass extraction in the liver (extraction ratio 0.66).</p>
<p><span class="Bold">Excretion:</span>Â Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration of radiolabeled pravastatin to normal volunteers, approximately 47% of total body clearance was via renal excretion and 53% by non-renal routes (i.e., biliary excretion and biotransformation).</p>
<p>Following single dose oral administration ofÂ <span class="Sup">14</span>C-pravastatin, the radioactive elimination tÂ½Â for pravastatin is 1.8 hours in humans.</p>
<p><span class="Bold">Specific Populations</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span>Â A single 20 mg oral dose of pravastatin was administered to 24 patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (as determined by creatinine clearance). No effect was observed on the pharmacokinetics of pravastatin or its 3Î±-hydroxy isomeric metabolite (SQ 31,906). Compared to healthy subjects with normal renal function, patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> had 69% and 37% higher mean AUC and C<span class="Sub">max</span>Â values, respectively, and a 0.61 hour shorter tÂ½Â for the inactive enzymatic ring hydroxylation metabolite (SQ 31,945).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span>Â In a study comparing the kinetics of pravastatin in patients with biopsy confirmed cirrhosis (N = 7) and normal subjects (N = 7), the mean AUC varied 18 fold in cirrhotic patients and 5 fold in healthy subjects. Similarly, the peak pravastatin values varied 47 fold for cirrhotic patients compared to 6 fold for healthy subjects [<span class="Italics">see Warnings and Precautions (5.2)</span>].</p>
<p><span class="Bold">Geriatric:</span>Â In a single oral dose study using pravastatin 20 mg, the mean AUC for pravastatin was approximately 27% greater and the mean cumulative urinary excretion (CUE) approximately 19% lower in elderly men (65 to 75 years old) compared with younger men (19 to 31 years old). In a similar study conducted in women, the mean AUC for pravastatin was approximately 46% higher and the mean CUE approximately 18% lower in elderly women (65 to 78 years old) compared with younger women (18 to 38 years old). In both studies, C<span class="Sub">max</span>, T<span class="Sub">max</span>, and tÂ½Â values were similar in older and younger subjects [<span class="Italics">see Use in Specific Populations (8.5)</span>].</p>
<p><span class="Bold">Pediatric:</span>Â After 2 weeks of once-daily 20 mg oral pravastatin administration, the geometric means of AUC were 80.7 (CV 44%) and 44.8 (CV 89%) ng*hr/mL for children (8 to 11 years, N = 14) and adolescents (12 to 16 years, N = 10), respectively. The corresponding values for C<span class="Sub">max</span>Â were 42.4 (CV 54%) and 18.6 ng/mL (CV 100%) for children and adolescents, respectively. No conclusion can be made based on these findings due to the small number of samples and large variability [<span class="Italics">see Use in Specific Populations (8.4)</span>].</p>
<p><span class="Bold">Drug-Drug Interactions</span></p>
<p><span class="Bold">Table 3: Effect of Coadministered Drugs on the Pharmacokinetics of Pravastatin</span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First"><span class="Bold">Coadministered Drug and Dosing<br>Regimen</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Pravastatin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Dose (mg)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Change in<br>AUC</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Change in<br>C<span class="Sub">max</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Cyclosporine 5 mg/kg single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 282%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 327%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Clarithromycin 500 mg BID for<br>9 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40 mg OD<br>for 8 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 110%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 128%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Boceprevir 800 mg TID for<br>6 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 63%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 49%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Darunavir 600 mg BID/Ritonavir<br>100 mg BID for 7 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 81%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 63%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Colestipol 10 g single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 47%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 53%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Cholestyramine 4 g single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Administered simultaneously</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">â†“Â 40%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 39%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Administered 1 hour prior toÂ <br>cholestyramine</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">â†‘Â 12%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 30%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Administered 4 hours after<br>cholestyramine</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">â†“Â 12%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 6.8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Cholestyramine 24 g OD for<br>4 weeks</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg BID<br>for 8 weeks</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 51%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 4.9%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">5 mg BID for<br>8 weeks</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 38%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 23%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">10 mg BID<br>for 8 weeks</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 18%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 33%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Fluconazole</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">200 mg IV for 6 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg PO +<br>10 mg IV</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 34%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 33%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">200 mg PO for 6 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg PO +<br>10 mg IV</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 16%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 16%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Kaletra 400 mg/100 mg BID<br>for 14 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg OD<br>for 4 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 33%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 26%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Verapamil IR 120 mg for 1 day and<br>Verapamil ER 480 mg for 3 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 31%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 42%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Cimetidine 300 mg QID for 3 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 30%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 9.8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Antacids 15 mL QID for 3 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 28%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 24%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Digoxin 0.2 mg OD for 9 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg OD<br>for 9 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 23%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 26%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Probucol 500 mg single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 14%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 24%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Warfarin 5 mg OD for 6 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg BID<br>for 6 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 13%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 6.7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Itraconazole 200 mg OD for 30 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40 mg OD<br>for 30 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 11%<br>(compared<br>to Day 1)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 17%<br>(compared<br>to Day 1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Gemfibrozil 600 mg single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 20%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Aspirin 324 mg single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 4.7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘8.9%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Niacin 1 g single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 3.6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 8.2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Diltiazem</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 2.7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 30%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Grapefruit juice</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40 mg single<br>dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†“Â 1.8%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 3.7%</p></td>
</tr>
</tbody>
</table>
<p>BID = twice daily; OD = once daily; QID = four times daily</p>
<p><span class="Bold">Table 4: Effect of Pravastatin on the Pharmacokinetics of Coadministered Drugs</span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Pravastatin Dosing Regimen</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Name and Dose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Change in<br>AUC</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Change in C<span class="Sub">max</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 mg BID for 6 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Warfarin 5 mg OD for<br>6 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 17%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 15%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">Change in mean<br><span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 0.4 sec</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 mg OD for 9 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Digoxin 0.2 mg OD for<br>9 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 4.6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 5.3%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 mg BID for 4 weeks</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Antipyrine 1.2 g single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â†‘Â 3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Not Reported</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">10 mg BID for 4 weeks</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">â†‘Â 1.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 mg BID for 4 weeks</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">â†‘Â Less than 1%</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 mg OD for 4 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Kaletra 400 mg/100 mg<br>BID for 14 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">No change</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">No change</p></td>
</tr>
</tbody>
</table>
<p>BID = twice daily; OD = once daily</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_7d6d20fe-cb0b-4c36-9633-eb110b29cc67"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_9f7a4fd5-5d50-47f8-83fe-3976048c96ce"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First">In a 2 year study in rats fed pravastatin at doses of 10, 30, or 100 mg/kg body weight, there was an increased incidence of hepatocellular carcinomas in males at the highest dose (p &lt; 0.01). These effects in rats were observed at approximately 12 times the human dose (HD) of 80 mg based on body surface area (mg/m<span class="Sup">2</span>) and at approximately 4 times the HD, based on AUC.</p>
<p>In a 2 year study in mice fed pravastatin at doses of 250 and 500 mg/kg/day, there was an increased incidence of hepatocellular carcinomas in males and females at both 250 and 500 mg/kg/day (p &lt; 0.0001). At these doses, lung <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in females were increased (p = 0.013). These effects in mice were observed at approximately 15 times (250 mg/kg/day) and 23 times (500 mg/kg/day) the HD of 80 mg, based on AUC. In another 2 year study in mice with doses up to 100 mg/kg/day (producing drug exposures approximately 2 times the HD of 80 mg, based on AUC), there were no drug-induced tumors.</p>
<p>No evidence of mutagenicity was observedÂ <span class="Italics">in vitro</span>, with or without rat-liver metabolic activation, in the following studies: microbial mutagen tests, using mutant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> ofÂ <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span>Â orÂ <span class="Italics">Escherichia coli</span>; a forward mutation assay in L5178Y TK +/âˆ’ mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells; a chromosomal aberration test in hamster cells; and a gene conversion assay usingÂ <span class="Italics">Saccharomyces cerevisiae</span>. In addition, there was no evidence of mutagenicity in either a dominant lethal test in mice or a micronucleus test in mice.</p>
<p>In a fertility study in adult rats with daily doses up to 500 mg/kg, pravastatin did not produce any adverse effects on fertility or general reproductive performance.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="LINK_081d33cc-cec0-475b-9c32-2045d5c9320e"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Bold">CNS Toxicity</span></p>
<p>CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and mononuclear cell infiltration of perivascular spaces, were seen in dogs treated with pravastatin at a dose of 25 mg/kg/day. These effects in dogs were observed at approximately 59 times the HD of 80 mg/day, based on AUC. Similar CNS vascular lesions have been observed with several other drugs in this class.</p>
<p>A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion starting at 60 mg/kg/day, a dose that produced mean plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose (as measured by total enzyme inhibitory activity). This same drug also produced vestibulocochlear Wallerian-like degeneration and retinal <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> cell chromatolysis in dogs treated for 14 weeks at 180 mg/kg/day, a dose which resulted in a mean plasma drug level similar to that seen with the 60 mg/kg/day dose.</p>
<p>When administered to juvenile rats (postnatal days [PND] 4 through 80 at 5 to 45 mg/kg/day), no drug related changes were observed at 5 mg/kg/day. At 15 and 45 mg/kg/day, altered body-<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was observed during the dosing and 52 day recovery periods as well as slight thinning of the corpus callosum at the end of the recovery period. This finding was not evident in rats examined at the completion of the dosing period and was not associated with any inflammatory or degenerative changes in the brain. The biological relevance of the corpus callosum finding is uncertain due to the absence of any other microscopic changes in the brain or peripheral nervous tissue and because it occurred at the end of the recovery period. Neurobehavioral changes (enhanced acoustic startle responses and increased errors in water-maze learning) combined with evidence of generalized toxicity were noted at 45 mg/kg/day during the later part of the recovery period. Serum pravastatin levels at 15 mg/kg/day are approximately â‰¥ 1 times (AUC) the maximum pediatric dose of 40 mg. No thinning of the corpus callosum was observed in rats dosed with pravastatin (â‰¥ 250 mg/kg/day) beginning PND 35 for 3 months suggesting increased sensitivity in younger rats. PND 35 in a rat is approximately equivalent to an 8 to 12-year-old human child. Juvenile male rats given 90 times (AUC) the 40 mg dose had decreased fertility (20%) with sperm abnormalities compared to controls.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_0e056b66-5afb-4732-a3a7-799c94b07bf8"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><span class="Bold">14.1 Prevention of Coronary Heart Disease</span></p>
<p>In the Pravastatin Primary Prevention Study (WOS),3Â the effect of pravastatin sodium on fatal and nonfatal CHD was assessed in 6595Â <br>men 45 to 64 years of age, without a previous MI, and with LDL-C levels between 156 to 254 mg/dL (4 to 6.7 mmol/L). In this randomized, double-blind, placebo-controlled study, patients were treated with standard care, including dietary advice, and either pravastatin 40 mg daily (N = 3302) or placebo (N = 3293) and followed for a median duration of 4.8 years. Median (25<span class="Sup">th</span>, 75<span class="Sup">th</span>Â percentile) percent changes from baseline after 6 months of pravastatin treatment in Total-C, LDL-C, TG, and HDL-C were âˆ’20.3 (âˆ’26.9, âˆ’11.7), âˆ’27.7 (âˆ’36, âˆ’16.9), âˆ’9.1 (âˆ’27.6, 12.5), and 6.7 (âˆ’2.1, 15.6), respectively.</p>
<p>Pravastatin sodium significantly reduced the rate of first coronary events (either CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or nonfatal MI) by 31% (248 events in the placebo group [CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> = 44, nonfatal MI = 204] versus 174 events in the pravastatin sodium group [CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> = 31, nonfatal MI = 143], p = 0.0001 [see figure below]). The risk reduction with pravastatin sodium was similar and significant throughout the entire range of baseline LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. This reduction was also similar and significant across the age range studied with a 40% risk reduction for patients younger than 55 years and a 27% risk reduction for patients 55 years and older. The Pravastatin Primary Prevention Study included only men, and therefore it is not clear to what extent these data can be extrapolated to a similar population of female patients.</p>
<p>Pravastatin sodium also significantly decreased the risk for undergoing myocardial revascularization procedures (coronary artery bypass graft [CABG] surgery or percutaneous transluminal coronary angioplasty [PTCA]) by 37% (80 vs 51 patients, p = 0.009) and coronary angiography by 31% (128 vs 90, p = 0.007). Cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were decreased by 32% (73 vs 50, p = 0.03) and there was no increase in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from non-cardiovascular causes.</p>
<p><span class="Bold">14.2 Secondary Prevention of Cardiovascular Events</span></p>
<p>In the PLAC I<span class="Sup">6</span>Â study, the effect of pravastatin therapy on <span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span> was assessed by coronary angiography in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary disease</span> and moderate <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (baseline LDL-C range: 130 to 190 mg/dL). In this double-blind, multicenter, controlled clinical trial, angiograms were evaluated at baseline and at 3 years in 264 patients. Although the difference between pravastatin and placebo for the primary endpoint (per-patient change in mean coronary artery diameter) and 1 of 2 secondary endpoints (change in percent lumen diameter stenosis) did not reach statistical significance, for the secondary endpoint of change in minimum lumen diameter, statistically significant slowing of disease was seen in the pravastatin treatment group (p = 0.02).</p>
<p>In the REGRESS<span class="Sup">7</span>Â study, the effect of pravastatin on <span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span> was assessed by coronary angiography in 885 patients with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, angiographically documented <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, and <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span> (baseline total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> range: 160 to 310 mg/dL). In this double-blind, multicenter, controlled clinical trial, angiograms were evaluated at baseline and at 2 years in 653 patients (323 treated with pravastatin). Progression of <span class="product-label-link" type="condition" conceptid="4194618" conceptname="Coronary artery atheroma">coronary atherosclerosis</span> was significantly slowed in the pravastatin group as assessed by changes in mean segment diameter (p = 0.037) and minimum obstruction diameter (p = 0.001).</p>
<p>Analysis of pooled events from PLAC I, PLAC II,<span class="Sup">8</span>Â REGRESS, and KAPS<span class="Sup">9</span>Â studies (combined N = 1891) showed that treatment with pravastatin was associated with a statistically significant reduction in the composite event rate of fatal and nonfatal MI (46 events or 6.4% for placebo versus 21 events or 2.4% for pravastatin, p = 0.001). The predominant effect of pravastatin was to reduce the rate of nonfatal MI.</p>
<p><span class="Bold">14.3 Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (<span class="Italics">Fredrickson</span>Â Types IIa and IIb)</span></p>
<p>Pravastatin sodium is highly effective in reducing Total-C, LDL-C, and TG in patients with heterozygous familial, presumed familial combined, and non-familial (non-FH) forms of primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. A therapeutic response is seen within 1 week, and the maximum response usually is achieved within 4 weeks. This response is maintained during extended periods of therapy. In addition, pravastatin sodium is effective in reducing the risk of acute coronary events in hypercholesterolemic patients with and without previous MI.</p>
<p>A single daily dose is as effective as the same total daily dose given twice a day. In multicenter, double-blind, placebo-controlled studies of patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, treatment with pravastatin in daily doses ranging from 10 to 40 mg consistently and significantly decreased Total-C, LDL-C, TG, and Total-C/HDL-C and LDL-C/HDL-C ratios (see Table 7).</p>
<p>In a pooled analysis of 2 multicenter, double-blind, placebo-controlled studies of patients with primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, treatment with pravastatin at a daily dose of 80 mg (N = 277) significantly decreased Total-C, LDL-C, and TG. The 25<span class="Sup">th</span>Â and 75<span class="Sup">th</span>Â percentile changes from baseline in LDL-C for pravastatin 80 mg were âˆ’43% and âˆ’30%. The efficacy results of the individual studies were consistent with the pooled data (see Table 7).</p>
<p>Treatment with pravastatin sodium modestly decreased VLDL-C and pravastatin sodium across all doses produced variable increases in HDL-C (see Table 7).</p>
<table>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="5"><p class="First"><span class="Bold">Table 7: Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> Studies: Dose Response of Pravastatin Sodium Once Daily Administration</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Dose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Total-C</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">LDL-C</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">HDL-C</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">TG</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">Mean Percent Changes From Baseline After 8 Weeks<span class="Sup">a</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Placebo (N = 36)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">+1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">10 mg (N = 18)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’16%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’22%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">+7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’15%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 mg (N = 19)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’24%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’32%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">+2%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’11%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">40 mg (N = 18)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’25%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’34%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">+12%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’24%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">Mean Percent Changes From Baseline After 6 Weeks<span class="Sup">b</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Placebo (N = 162)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">+1%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">80 mg (N = 277)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’27%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’37%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">+3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’19%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> A multicenter, double-blind, placebo-controlled study.</p>
<p><span class="Sup">b</span> Pooled analysis of 2 multicenter, double-blind, placebo-controlled studies.</p>
<p>In another clinical trial, patients treated with pravastatin in combination with cholestyramine (70% of patients were taking cholestyramine 20 or 24 g per day) had reductions equal to or greater than 50% in LDL-C. Furthermore, pravastatin attenuated cholestyramine-induced increases in TG levels (which are themselves of uncertain clinical significance).</p>
<p><span class="Bold">14.4 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (<span class="Italics">FredricksonÂ </span>Type IV)</span></p>
<p>The response to pravastatin in patients with Type IV <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (baseline TG &gt; 200 mg/dL and LDL-C &lt; 160 mg/dL) was evaluated in a subset of 429 patients. For pravastatin-treated subjects, the median (min, max) baseline TG level was 246 (200.5, 349.5) mg/dL (see Table 8).</p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First"><span class="Bold">Table 8: Patients WithÂ <span class="Italics">Fredrickson</span>Â Type IV <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> Median (25<span class="Sup">th</span>, 75<span class="Sup">th</span>Â Percentile) % Change From Baseline</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First"><span class="Bold">Pravastatin 40 mg (N = 429)</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Placebo (N = 430)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">TG</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">âˆ’21.1 (âˆ’34.8, 1.3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">âˆ’6.3 (âˆ’23.1, 18.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Total-C</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">âˆ’22.1 (âˆ’27.1, âˆ’14.8)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.2 (âˆ’6.9, 6.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">LDL-C</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">âˆ’31.7 (âˆ’39.6, âˆ’21.5)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0.7 (âˆ’9.0, 10)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">HDL-C</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.4 (âˆ’1.2, 17.7)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2.8 (âˆ’5.7, 11.7)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Non-HDL-C</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">âˆ’27.2 (âˆ’34, âˆ’18.5)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">âˆ’0.8 (âˆ’8.2, 7)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">14.5 Dysbetalipoproteinemia (<span class="Italics">Fredrickson</span>Â Type III)</span></p>
<p>The response to pravastatin in two double-blind crossover studies of 46 patients with genotype E2/E2 and Fredrickson Type III dysbetalipoproteinemia is shown inÂ <span class="Bold">Table 9</span>.</p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First"><span class="Bold">Table 9: Patients WithÂ <span class="Italics">Fredrickson</span>Â Type III Dysbetalipoproteinemia Median (min, max) % Change From Baseline</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">Median (min, max) at<br>Baseline (mg/dL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Median % Change (min, max)<br>Pravastatin 40 mg (N = 20)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics">Study 1</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Total-C</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">386.5 (245, 672)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’32.7 (âˆ’58.5, 4.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">TG</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">443 (275, 1299)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’23.7 (âˆ’68.5, 44.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">VLDL-C<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">206.5 (110, 379)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’43.8 (âˆ’73.1, âˆ’14.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">LDL-C<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">117.5 (80, 170)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’40.8 (âˆ’63.7, 4.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">HDL-C</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30 (18, 88)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.4 (âˆ’45, 105.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Non-HDL-C</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">344.5 (215, 646)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’36.7 (âˆ’66.3, 5.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First">Median (min, max) at<br>Baseline (mg/dL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Median % Change (min, max)<br>Pravastatin 40 mg (N = 26)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Italics">Study 2</span></p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Total-C</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">340.3 (230.1, 448.6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’31.4 (âˆ’54.5, âˆ’13)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">TG</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">343.2 (212.6, 845.9)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’11.9 (âˆ’56.5, 44.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">VLDL-C</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">145 (71.5, 309.4)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’35.7 (âˆ’74.7, 19.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">LDL-C</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">128.6 (63.8, 177.9)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’30.3 (âˆ’52.2, 13.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">HDL-C</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">38.7 (27.1, 58)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5 (âˆ’17.7, 66.7)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Non-HDL-C</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">295.8 (195.3, 421.5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’35.5 (âˆ’81, âˆ’13.5)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> N = 14</p>
<p><span class="Bold">14.6 Pediatric Clinical Study</span></p>
<p>A double-blind, placebo-controlled study in 214 patients (100 boys and 114 girls) with <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">heterozygous familial hypercholesterolemia</span> (HeFH), aged 8 to 18 years was conducted for 2 years. The children (aged 8 to 13 years) were randomized to placebo (N = 63) or 20 mg of pravastatin daily (N = 65) and the adolescents (aged 14 to 18 years) were randomized to placebo (N = 45) or 40 mg of pravastatin daily (N = 41). Inclusion in the study required an LDL-C level &gt; 95<span class="Sup">th</span>Â percentile for age and sex and one parent with either a clinical or molecular diagnosis of familial <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>. The mean baseline LDL-C value was 239 mg/dL and 237 mg/dL in the pravastatin (range: 151 to 405 mg/dL) and placebo (range: 154 to 375 mg/dL) groups, respectively.</p>
<p>Pravastatin significantly decreased plasma levels of LDL-C, Total-C, and ApoB in both children and adolescents (see Table 10). The effect of pravastatin treatment in the 2 age groups was similar.</p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold">Table 10: Lipid-Lowering Effects of Pravastatin in Pediatric Patients With <span class="product-label-link" type="condition" conceptid="4134862" conceptname="Familial hypercholesterolemia">Heterozygous Familial Hypercholesterolemia</span>: Least-Squares Mean % Change From Baseline at Month 24 (Last Observation Carried Forward: Intent-to-Treat)a</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td><p class="First"><span class="Bold">Pravastatin<br>20 mg<br>(Aged 8 to<br>13 years)<br>N = 65</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Pravastatin<br>40 mg<br>(Aged 14 to<br>18 years)<br>N = 41</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Combined Pravastatin<br>(Aged 8 to<br>18 years)<br>N = 106</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Combined<br>Placebo<br>(Aged 8 to<br>18 years)<br>N = 108</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">95% CI of the<br>Difference<br>Between<br>Combined Pravastatin and<br>Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">LDL-C</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’26.04b</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’21.07b</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’24.07b</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’1.52</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(âˆ’26.74, âˆ’18.86)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">TC</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’20.75b</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’13.08b</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’17.72b</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’0.65</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(âˆ’20.40, âˆ’13.83)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">HDL-C</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.04</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13.71</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.97</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3.13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(âˆ’1.71, 7.43)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">TG</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’9.58</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’0.30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’5.88</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’3.27</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(âˆ’13.95, 10.01)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">ApoB (N)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’23.16bÂ (61)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’18.08bÂ (39)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’21.11bÂ (100)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">âˆ’0.97 (106)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">(âˆ’24.29, âˆ’16.18)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> The above least-squares mean values were calculated based on log-transformed lipid values.</p>
<p><span class="Sup">b</span> Significant at p â‰¤ 0.0001 when compared with placebo.</p>
<p>The mean achieved LDL-C was 186 mg/dL (range: 67 to 363 mg/dL) in the pravastatin group compared to 236 mg/dL (range: 105 to 438 mg/dL) in the placebo group.</p>
<p>The safety and efficacy of pravastatin doses above 40 mg daily have not been studied in children. The long-term efficacy of pravastatin therapy in childhood to reduce morbidity and mortality in adulthood has not been established.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_d86fbc5a-14ea-4472-b8ed-e2ab825ee382"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">1. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - An integrated approach to mechanisms and disorders.Â <span class="Italics">N Engl J Med.</span>Â 1967;276: 34-44, 94-103, 148-156, 215-225, 273-281.</p>
<p>2. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy.Â <span class="Italics">Reprod Toxicol.</span>Â 1996;10(6):439-446.</p>
<p>3. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group (WOS). Prevention of coronary heart disease with pravastatin in men with <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>.Â <span class="Italics">N Engl J Med.</span>Â 1995;333:1301-1307.</p>
<p>6. Pitt B, Mancini GBJ, Ellis SG, et al, for the PLAC I Investigators. Pravastatin limitation of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> in the coronary arteries (PLAC I): Reduction in <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> progression and clinical events.Â <span class="Italics">J Am Coll Cardiol.</span>Â 1995;26:1133-1139.</p>
<p>7. Jukema JW, Bruschke AVG, van Boven AJ, et al, for the Regression Growth Evaluation Statin Study Group (REGRESS). Effects of lipid lowering by pravastatin on progression and regression of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> in symptomatic man with normal to moderately elevated serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels.Â <span class="Italics">Circ.</span>Â 1995;91:2528-2540.</p>
<p>8. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> in the carotid arteries: Design features of a clinical trial with carotid <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span> outcome (PLAC II).Â <span class="Italics">Control Clin Trials.</span>Â 1992;13:495-506.</p>
<p>9. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.Â <span class="Italics">Circ.</span>Â 1995;92:1758-1764.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_981fab02-d031-4e98-ab78-170ce5ea77eb"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8dd2b5a0-0a94-480d-8c22-7d34700fe4f9"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First"><span class="Bold">Pravastatin sodium tablets USP</span>Â are supplied as:</p>
<p><span class="Bold">20 mg tablets:</span>Â Light-yellow, unscored, round tablet, debossed â€œTEVAâ€? on one side and â€œ7201â€? on the other side in adherence packages of 30.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c7446438-35e7-4e7e-9095-e9d165c091fa"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature]. Protect from moisture. Protect from light.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_bb5dac0d-26d3-45fb-a52c-385960eb3b53"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised to report promptly unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if these muscle signs or symptoms persist after discontinuing pravastatin sodium [<span class="Italics">see Warnings and Precautions (5.1)</span>].</p>
<p>It is recommended that liver enzyme tests be performed before the initiation of pravastatin, and thereafter when clinically indicated. All patients treated with pravastatin should be advised to promptly report any symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> [<span class="Italics">see Warnings and Precautions (5.2)</span>].</p>
<p>Manufactured In Czech Republic By:</p>
<p><span class="Bold">TEVA Czech Industries, s.r.o.</span></p>
<p>Opava-Komarov, Czech Republic</p>
<p>Packaged by:</p>
<p><span class="Bold">International Labs, Inc.</span></p>
<p>St. Petersburg, FL 33710</p>
<p>Distributed by:</p>
<p><span class="Bold">The Kroger Co.</span></p>
<p>Cincinnati, OH 45202</p>
<p>Rev.Â 06/13Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  LI0049</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_03908a9d-b45a-4afd-a394-8134eb3c44e4"></a><a name="section-17"></a><p></p>
<h1>Pravastatin 20mg Carton</h1>
<p class="First">Â LC0012 JAC</p>
<div class="Figure">
<img alt="Pravastatin 20mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88295e57-9167-48a0-b52f-6ec9cef61109&amp;name=pravastatin-2.jpg"><p class="MultiMediaCaption">Pravastatin 20mg Carton</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRAVASTATIN SODIUMÂ 		
					</strong><br><span class="contentTableReg">pravastatin sodium tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54458-908(NDC:0093-7201)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PRAVASTATIN SODIUM</strong> (PRAVASTATIN) </td>
<td class="formItem">PRAVASTATIN SODIUM</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TEVA;7201</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54458-908-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076056</td>
<td class="formItem">02/20/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>International Labs, Inc.
							(023569924)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>26f55531-daef-4a98-960b-68b1cde73299</div>
<div>Set id: 88295e57-9167-48a0-b52f-6ec9cef61109</div>
<div>Version: 7</div>
<div>Effective Time: 20131022</div>
</div>
</div>Â <div class="DistributorName">International Labs, Inc.</div></p>
</body></html>
